Key statistics
On Tuesday, Annovis Bio Inc (ANVS:NYQ) closed at 2.58, 132.43% above the 52 week low of 1.11 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.67 |
|---|---|
| High | 2.67 |
| Low | 2.53 |
| Bid | 2.57 |
| Offer | 2.63 |
| Previous close | 2.67 |
| Average volume | 365.40k |
|---|---|
| Shares outstanding | 26.50m |
| Free float | 22.41m |
| P/E (TTM) | -- |
| Market cap | 70.76m USD |
| EPS (TTM) | -1.41 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
- Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
- Annovis to Host Corporate Update Webinar on January 28, 2026
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
- Annovis Announces Two Presentations at the CTAD 2025 Conference
- Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
- Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
- Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
- Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
More ▼
